Standardized Fecal Microbiota Transplantation for Crohn's Diseases

Launched by THE SECOND HOSPITAL OF NANJING MEDICAL UNIVERSITY · Feb 14, 2013

Keywords

ClinConnect Summary

This clinical trial is studying the use of fecal microbiota transplantation (FMT) as a treatment for Crohn's disease, a type of inflammatory bowel disease (IBD). FMT involves transferring healthy bacteria from a donor's stool into the intestines of a patient to help restore the balance of gut bacteria, which may improve symptoms and overall health. The researchers want to see how effective, safe, and lasting this treatment can be for at least 500 patients over a ten-year period.

To participate in the trial, individuals must have a clinical diagnosis of Crohn's disease that has not changed for at least three months and be willing to undergo the FMT procedure. However, people with serious health conditions, such as certain cancers or severe heart and liver problems, will not be eligible. Participants can expect close monitoring throughout the trial to ensure their safety and to assess how well the treatment is working. This trial is an important step in understanding how FMT might help those struggling with Crohn's disease.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Clinical diagnosis of Crohn's disease, with the diagnosis remaining unchanged after at least three months of follow-up.
• • Willingness to undergo FMT (Fecal Microbiota Transplantation).
• Exclusion Criteria:
• • Presence of serious conditions that made them unsuitable for inclusion (e.g., malignant neoplasms, cardiopulmonary failure, serious liver or kidney disease).